Siro Medical Writing Profile
Key Indicators
- Authorised Capital ₹ 12.15 Cr
as on 03-01-2025
- Paid Up Capital ₹ 12.01 Cr
as on 03-01-2025
- Company Age 2 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
About Siro Medical Writing
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 12.15 Cr and a paid-up capital of Rs 12.01 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Siro Medical Writing Private Limited India is Tanzeelah Shaikh as COMPANY SECRETARY. Karan Daftary, Akshay Daftary, and Gautam Daftary serve as directors at the Company.
- CIN/LLPIN
U72900MH2022PTC388105
- Company No.
388105
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Aug 2022
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Siro Medical Writing?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Tanzeelah Shaikh | Company Secretary | 15-Mar-2023 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karan Daftary  | Director | 22-Dec-2022 | Current |
| Akshay Daftary | Director | 05-Aug-2024 | Current |
| Gautam Daftary | Director | 22-Dec-2022 | Current |
Financial Performance of Siro Medical Writing.
Siro Medical Writing Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Siro Medical Writing?
In 2023, Siro Medical Writing had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Siro Clinpharm Private LimitedActive 24 years 10 monthsKaran Daftary, Akshay Daftary and 1 more are mutual person
- Siro Clintech Private LimitedActive 2 years 5 months
Karan Daftary, Akshay Daftary and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Siro Medical Writing?
Siro Medical Writing has a workforce of 0 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Siro Medical Writing, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Siro Medical Writing's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
